Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
| ▸ | FGF2 | P09038 | 1/20 | 0.33 |
| ▸ | HK2 | P52789 | 5/20 | 0.32 |
| ▸ | HK1 | P19367 | 4/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13286928 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL21067663 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL7209918 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL20987120 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL7209912 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL16728926 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL15449484 | 0.87 | F10 (0.36) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL29535532 | 0.85 | F10 (0.48) | F10F2SERPINC1FGF1FGF2 | |
| SCHEMBL29534894 | 0.85 | F10 (0.43) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL17340086 | 0.82 | F10 (0.57) | F10SERPINC1CA2FGF1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122575-A1 | TREATMENT FOR DISEASE MODIFICATION | EXTHERA MEDICAL CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024010609-A1 | PRISTINE GRAPHENE BASED BIOSENSOR FOR BIOMARKER DETECTION AND RELATED CORE PARTICLES, MATERIALS COMPOSITIONS METHODS AND SYSTEMS | HAWKEYE BIO, LIMITED (IE) | 2024-01-11 | — | — | WO | disclosed |
| US-20230243853-A1 | METHOD OF IDENTIFYING BIOMARKERS OF NEUROLOGICAL DISEASES AND DIAGNOSIS OF NEUROLOGICAL DISEASES | CRC FOR MENTAL HEALTH LTD (AU) | 2023-08-03 | — | — | US | disclosed |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| WO-2021011566-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | PARSONS C LOWELL (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-3744334-A1 | METHOD FOR MANUFACTURING COMPOSITION COMPRISING LOCAL ANESTHETIC, HEPARINOID, AND BUFFER | Parsons, C. Lowell (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-2661271-B1 | METHOD FOR MANUFACTURING COMPOSITION COMPRISING LOCAL ANESTHETIC, HEPARINOID, AND BUFFER | PARSONS C LOWELL (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-5464815-A | Extending plasma half-life of selectin by coadministering with compound which inhibits binding of selectin to low affinity heparin-like site on surface of cells of organ perfused with blood; assaying sensitivity; pharmaceutical composition | GENENTECH, INC. (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1995024209-A1 | THERAPEUTIC USES OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN DIMER PRODUCTS | XOMA CORPORATION (US) | 1995-09-14 | — | — | WO | disclosed |
| US-5447913-A | Use to neutralize heparin and to treat endotoxemia; monomeric BPI protein product is amino terminal fragment having from about 1 to 193 to about 1 to 199 amino acids of the amino terminal of BPI protein; covalently linked dimer | XOMA CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| WO-1995007097-A1 | INHIBITION OF HEPARIN-BINDING | GENENTECH, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0287477-B1 | Low molecular weight heparins with a regular structure, their preparation and biological uses | SANOFI SA (FR) | 1994-11-02 | — | — | EP | disclosed |
| US-5348942-A | Therapeutic uses of bactericidal/permeability increasing protein products | XOMA CORPORATION (US) | 1994-09-20 | — | — | US | disclosed |
| WO-1994020128-A1 | THERAPEUTIC USES OF BACTERICIDAL/PERMEABILITY INCREASING PROTEIN PRODUCTS | XOMA CORPORATION (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5272261-A | Preparation of sulfated polysaccharide fractions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0406512-B1 | POLYSACCHARIDE FRACTION WITH ANTI-HIV ACTIVITY | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-16 | — | — | EP | disclosed |
| EP-0406512-A1 | Polysaccharide fraction with anti-HIV activity | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | F10 1731/4885AMDHD2 1071/4885F2 3440/4885 |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | F10 1731/4885AMDHD2 1071/4885F2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.